Inhibrx Biosciences stock reports a 48.3 percent response rate

Inhibrx Biosciences stock was trading at USD 100.05 on Nasdaq on September 24, 2026, down 0.28 percent from the previous close. The company is advancing INBRX-106 after Phase 2 data showed a 48.3 percent response rate with pembrolizumab versus 26.5 percent for pembrolizumab alone, according to the SEC filing.

Response rate reaches 48.3 percent

The randomized Phase 2 portion of the HexAgon study included 68 patients, with 63 evaluable for the primary endpoint analysis. The combination arm produced a confirmed objective response rate of 48.3 percent, compared with 26.5 percent for pembrolizumab monotherapy.

The result represents an 82.3 percent relative advantage for the combination arm based on the reported response rates. Reuters reported on September 8, 2026, that the trial involved patients with metastatic or inoperable head and neck squamous cell carcinoma.

Progression-free survival sets the next test

Median progression-free survival reached 9.6 months with INBRX-106 plus pembrolizumab, versus 4.9 months with pembrolizumab alone, according to the September 8, 2026 filing. Six-month progression-free survival was 72.4 percent in the combination arm and 42.8 percent in the control arm.

The HPV-positive subgroup delivered an 80.0 percent response rate with the combination and 33.3 percent with pembrolizumab alone. Inhibrx plans to expand the randomized Phase 2 study and then align with the U.S. Food and Drug Administration on a potential confirmatory development path.

Director buys at USD 100.00

Director Jon Faiz Kayyem purchased 5,000 shares at USD 100.00 each on September 23, 2026, for a total of USD 500,000, according to Investing.com. The purchase price was USD 0.05 below the intraday quote of USD 100.05 on September 24, 2026.

INBX had a market capitalization of USD 1,467,778,803 on September 24, 2026. Its 52-week range was USD 28.16 to USD 155.29, placing the current quote 35.6 percent below the yearly high.